Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhlis Cem Ar

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2024
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid LeukemiaÖzge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, et al.
Advances in Laboratory Medicine|June 26, 2023
Upregulation of SPINK2 in acute myeloid leukemiaSümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 16, 2019
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 RecommendationsTeoman Soysal, Ahmet Emre Eskazan, Istemi Serin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 8, 2026
Haemophilia Management in Natural Disasters-From Field to Consensus ReportAhmet Muzaffer Demir, Selin Aytaç, Serap Karaman, et al.
Leukemia Research|May 17, 2014
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusionAhmet Emre Eskazan, Deniz Eyice, Enes Ali Kurt, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|May 27, 2024
Management of Primary Immune Thrombocytopenia: Turkish Modified Delphi-Based Consensus Statement for Special ConsiderationsElif Gülsüm Ümit, Ahmet Muzaffer Demir, Muhlis Cem Ar, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|March 28, 2024
Management of Adult Primary Immune Thrombocytopenia: Delphi-Based Consensus RecommendationsAhmet Muzaffer Demir, Elif Gülsüm Ümit, Muhlis Cem Ar, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 30, 2021
Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center ExperienceAhmet Emre Eşkazan, Deniz Özmen, Mert Öztaş, et al.
Leukemia Research|April 10, 2024
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experienceSüreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, et al.
Leukemia & Lymphoma|July 3, 2018
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitorsYucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2024
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid LeukemiaÖzge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, et al.
Advances in Laboratory Medicine|June 26, 2023
Upregulation of SPINK2 in acute myeloid leukemiaSümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 16, 2019
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 RecommendationsTeoman Soysal, Ahmet Emre Eskazan, Istemi Serin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 8, 2026
Haemophilia Management in Natural Disasters-From Field to Consensus ReportAhmet Muzaffer Demir, Selin Aytaç, Serap Karaman, et al.
Leukemia Research|May 17, 2014
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusionAhmet Emre Eskazan, Deniz Eyice, Enes Ali Kurt, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|May 27, 2024
Management of Primary Immune Thrombocytopenia: Turkish Modified Delphi-Based Consensus Statement for Special ConsiderationsElif Gülsüm Ümit, Ahmet Muzaffer Demir, Muhlis Cem Ar, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|March 28, 2024
Management of Adult Primary Immune Thrombocytopenia: Delphi-Based Consensus RecommendationsAhmet Muzaffer Demir, Elif Gülsüm Ümit, Muhlis Cem Ar, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 30, 2021
Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center ExperienceAhmet Emre Eşkazan, Deniz Özmen, Mert Öztaş, et al.
Leukemia Research|April 10, 2024
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experienceSüreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, et al.
Leukemia & Lymphoma|July 3, 2018
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitorsYucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, et al.
Pageof 11